Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC. However, due to the fact that most patients are already in the middle and late stages of treatment, only about 20% of patients have the opportunity to undergo surgical resection. Palliative cytoreductive surgery has been used in the treatment of a variety of malignant tumors, but it is not recommended for the treatment of HCC. Under the premise of targeted therapy and immunotherapy, palliative hepatectomy can reduce tumor burden and may further improve the therapeutic effect of HCC. The aim of this study is to explore whether palliative hepatectomy combined with targeted therapy and immunotherapy can improve the therapeutic effect of advanced HCC, ultimately prolong the survival time of patients, and provide a new treatment direction for patients with advanced HCC.

NCT Number	NCT06470256
Lead Sponsor	Zhiyong Huang Collaborators: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhongnan Hospital, Renmin Hospital of Wuhan University, Taihe Hospital, Hubei Cancer Hospital, Xiangyang Central Hospital, Wuhan Central Hospital
Conditions	Advanced Hepatocellular Carcinoma
Enrollment	50 participants
Start Date	2024-06-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-06-24